Weiss Ratings Reiterates Sell (E+) Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Key Points

• Weiss Ratings has reaffirmed a "sell (E+)" rating for Ultragenyx Pharmaceutical (NASDAQ:RARE) amidst varying opinions from other brokerages.
• Several analysts have lowered their price targets for the company's stock, with an average target price now at $81.50 and a consensus rating of "Moderate Buy."
• Ultragenyx recently reported a quarterly revenue of $166.5 million, surpassing analysts' estimates, but had a negative earnings per share of ($1.17).

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by equities research analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

A number of other brokerages also recently issued reports on RARE. Canaccord Genuity Group lowered their price target on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Morgan Stanley cut their price target on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a report on Monday, July 14th. Cantor Fitzgerald restated an "overweight" rating and set a $105.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, September 5th. Wedbush cut their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research note on Monday, July 14th. Finally, Wells Fargo & Company lowered their price target on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a research report on Thursday, July 10th. Eleven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical presently has an average rating of "Moderate Buy" and an average target price of $81.50.

Ultragenyx Pharmaceutical Trading Up 3.8%

Shares of NASDAQ:RARE traded up $1.12 on Wednesday, hitting $30.86. The company had a trading volume of 1,276,100 shares, compared to its average volume of 1,802,452. Ultragenyx Pharmaceutical has a 52-week low of $25.81 and a 52-week high of $57.99. The business has a 50 day moving average of $29.60 and a 200 day moving average of $33.16. The company has a market cap of $2.97 billion, a PE ratio of -5.58 and a beta of 0.21.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The firm had revenue of $166.50 million during the quarter, compared to analyst estimates of $161.37 million. During the same quarter in the prior year, the firm posted ($1.52) EPS. Ultragenyx Pharmaceutical's revenue was up 13.2% compared to the same quarter last year. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Karah Herdman Parschauer sold 2,450 shares of the business's stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $31.17, for a total transaction of $76,366.50. Following the completion of the sale, the executive vice president owned 73,271 shares in the company, valued at $2,283,857.07. The trade was a 3.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 5.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of RARE. GAMMA Investing LLC increased its stake in Ultragenyx Pharmaceutical by 76.2% in the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 323 shares during the last quarter. Xponance Inc. lifted its holdings in Ultragenyx Pharmaceutical by 2.8% in the first quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company's stock worth $455,000 after purchasing an additional 347 shares during the period. Oak Ridge Investments LLC raised its position in Ultragenyx Pharmaceutical by 2.3% during the first quarter. Oak Ridge Investments LLC now owns 17,757 shares of the biopharmaceutical company's stock valued at $643,000 after buying an additional 395 shares during the period. Teacher Retirement System of Texas grew its stake in shares of Ultragenyx Pharmaceutical by 1.8% in the second quarter. Teacher Retirement System of Texas now owns 22,773 shares of the biopharmaceutical company's stock worth $828,000 after acquiring an additional 404 shares during the last quarter. Finally, GF Fund Management CO. LTD. boosted its stake in shares of Ultragenyx Pharmaceutical by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 2,364 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 425 shares during the last quarter. Institutional investors own 97.67% of the company's stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.